文献速递泌尿生殖腹部MR

前列腺影像报告和数据系统第2版在前列腺MRI检出和评估前列腺癌病灶中的阅片者间变异

Interreader Variability of Prostate Imaging Reporting and Data System Version 2 in Detecting and Assessing Prostate Cancer Lesions at Prostate MRI.
PubMed 文献 · AJR Am J Roentgenol · 2019-03-27

研究纳入163例未治疗患者行3T多参数MRI,9名不同经验放射科医师用PI-RADSv2阅片,以前列腺切除标本为金标准。指标病灶检出敏感度80.9%,高经验者患者水平特异度84.0% vs 其他55.2%;指标病灶PI-RADS分类一致性中等(κ=0.419),PI-RADS 3一致性轻微,移行区T2WI PI-RADS 4一致性低。

要点

  • 指标病灶检出敏感度80.9%(95%CI 75.1-85.9%),不同经验组间无显著差异(p=0.392)。
  • 指标病灶PI-RADSv2分类一致性中等(κ=0.419;95%CI 0.238-0.595)。
  • PI-RADS 3一致性轻微(0.208),PI-RADS 4一致性较好(0.674),但移行区T2WI PI-RADS 4仅0.250。

核心结论

  • 不同经验放射科医师用PI-RADSv2检出指标病灶一致性极好,病灶分类一致性中等;未来PI-RADS版本应澄清移行区PI-RADS 3和4。

研究设计与样本

  • 回顾性分析2012年4月至2015年6月未治疗患者3T多参数MRI,163例中110例MRI后行前列腺切除术、53例MRI正常且经直肠超声引导活检;9名放射科医师(高、中、低经验各3名)平均阅58例(范围56-60),以前列腺切除标本配准MRI为金标准。

关键影像表现/征象

  • 放射科医师共检出336个病灶。
  • 高经验者患者水平特异度84.0%,其他阅片者55.2%(p<0.001)。
  • 指标病灶检出阅片者间一致性极好(指数0.871;95%CI 0.798-0.923)。
  • 优势病灶一致性极好(0.828;95%CI 0.742-0.913)。

诊断标准与关键数值

  • 指标病灶检出敏感度80.9%(95%CI 75.1-85.9%),不同经验组间无显著差异(p=0.392)。
  • 指标病灶PI-RADSv2分类一致性中等(κ=0.419;95%CI 0.238-0.595)。
  • PI-RADS 3分类一致性轻微(0.208;95%CI 0.086-0.284),PI-RADS 4一致性较好(0.674;95%CI 0.540-0.776)。
  • 移行区T2WI PI-RADS 4一致性0.250(95%CI 0.108-0.372)。

临床应用与阅片要点

  • 高经验阅片者患者水平特异度84.0% vs 其他55.2%(p<0.001),提示经验影响特异性。
  • PI-RADS 3和移行区T2WI PI-RADS 4一致性低,报告时需注意分类的阅片者间差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE. The purpose of this study was to evaluate agreement among radiologists in detecting and assessing prostate cancer at multiparametric MRI using Prostate Imaging Reporting and Data System version 2 (PI-RADSv2). MATERIALS AND METHODS. Treatment-naïve patients underwent 3-T multipara-metric MRI between April 2012 and June 2015. Among the 163 patients evaluated, 110 underwent prostatectomy after MRI and 53 had normal MRI findings and transrectal ultrasound-guided biopsy results. Nine radiologists participated (three each with high, intermediate, and low levels of experience). Readers interpreted images of 58 patients on average (range, 56-60) using PI-RADSv2. Prostatectomy specimens registered to MRI were ground truth. Interob-server agreement was evaluated with the index of specific agreement for lesion detection and kappa and proportion of agreement for PI-RADS category assignment. RESULTS. The radiologists detected 336 lesions. Sensitivity for index lesions was 80.9% (95% CI, 75.1-85.9%), comparable across reader experience (p = 0.392). Patient-level specificity was experience dependent; highly experienced readers had 84.0% specificity versus 55.2% for all others (p < 0.001). Interobserver agreement was excellent for detecting index lesions (index of specific agreement, 0.871; 95% CI, 0.798-0.923). Agreement on PI-RADSv2 category assignment of index lesions was moderate (κ = 0.419; 95% CI, 0.238-0.595). For individual category assignments, proportion of agreement was slight for PI-RADS category 3 (0.208; 95% CI, 0.086-0.284) but substantial for PI-RADS category 4 (0.674; 95% CI, 0.540-0.776). However, proportion of agreement for T2-weighted PI-RADS 4 in the transition zone was 0.250 (95% CI, 0.108-0.372). Proportion of agreement for category assignment of index lesions on dynamic contrast-enhanced MR images was 0.822 (95% CI, 0.728-0.903), on T2-weighted MR images was 0.515 (95% CI, 0.430-0623), and on DW images was 0.586 (95% CI, 0.495-0.682). Proportion of agreement for dominant lesion was excellent (0.828; 95% CI, 0.742-0.913). CONCLUSION. Radiologists across experience levels had excellent agreement for detecting index lesions and moderate agreement for category assignment of lesions using PI-RADS. Future iterations of PI-RADS should clarify PI-RADS 3 and PI-RADS 4 in the transition zone.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Greer MD, Shih JH, Lay N, et al. Interreader Variability of Prostate Imaging Reporting and Data System Version 2 in Detecting and Assessing Prostate Cancer Lesions at Prostate MRI. AJR Am J Roentgenol. 2019. PMID: 30917023. doi:10.2214/AJR.18.20536

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。